1. A 59-year-old man with hypertension and HFrEF (EF 30%) presents to clinic with BP 162/94 mmHg. He is currently on sacubitril/valsartan 97/103 mg twice daily, spironolactone 25 mg daily, and furosemide 40 mg daily. He is euvolemic. His cardiologist wants to initiate a beta-blocker. Three months later, on carvedilol 6.25 mg twice daily (titrated up from 3.125 mg), his BP is 138/84 mmHg — still slightly above target — and his heart rate is 58 bpm. His EF on repeat echo has improved to 38%. His cardiologist considers further up-titration of carvedilol to 12.5 mg twice daily. Which of the following most accurately reflects the pharmacological reasoning behind continuing carvedilol uptitration despite the already-low heart rate?
A) The heart rate of 58 bpm indicates that maximum beta-1 receptor occupancy has been achieved; further dose increases will not provide additional mortality benefit and only increase adverse effect risk
B) Carvedilol should be stopped and replaced with bisoprolol at this point — bisoprolol's higher beta-1 selectivity will allow further dose titration without the bradycardia risk that carvedilol's non-selective blockade causes
C) The target dose in outcome trials (carvedilol 25 mg twice daily in COPERNICUS) provides mortality benefit that is partly independent of the degree of heart rate reduction — the intracellular signaling effects of beta-1 blockade on maladaptive ventricular remodeling require adequate receptor occupancy that may not be achieved at low doses; heart rate of 58 bpm is not a contraindication to uptitration as long as the patient remains asymptomatic (no dizziness, syncope, or hemodynamic compromise); uptitration should proceed carefully with monitoring
D) Further uptitration is contraindicated because the improved EF (38%) means the patient's HFrEF has resolved and beta-blocker therapy is no longer indicated; the drug should be tapered
E) The heart rate of 58 bpm mandates adding digoxin before further carvedilol uptitration — digoxin will accelerate the heart rate through its positive chronotropic effect, creating hemodynamic space for higher carvedilol doses
ANSWER: C
Rationale:
In HFrEF, the mortality benefit of beta-blockers is dose-dependent — the landmark trials achieved their outcomes at target doses (carvedilol 25 mg twice daily in COPERNICUS, metoprolol succinate 200 mg daily in MERIT-HF, bisoprolol 10 mg daily in CIBIS-II), and patients titrated to target doses had greater benefit than those on lower doses. The mechanisms underlying this benefit include both heart rate reduction (reducing myocardial oxygen demand and allowing better diastolic filling) and dose-dependent attenuation of maladaptive beta-1 receptor-mediated intracellular signaling — including PKA-mediated phospholamban hyperphosphorylation and CaMKII activation — that drives pathological hypertrophy, fibrosis, and cardiomyocyte apoptosis. These signaling effects require adequate receptor occupancy that may not be fully achieved at low doses. A heart rate of 58 bpm in an asymptomatic patient is not a contraindication to further uptitration — bradycardia becomes clinically relevant when it causes symptoms (dizziness, presyncope, fatigue) or hemodynamic compromise. The appropriate approach is to continue titration with monitoring, not to plateau at the first sign of a lower-than-normal heart rate. The improved EF is an expected response to GDMT and is not a reason to stop or plateau beta-blocker therapy — it reflects treatment success.
Option A: Option A is incorrect because maximum receptor occupancy and maximum mortality benefit are achieved at target doses, not at whatever dose produces a given heart rate.
Option B: Option B is incorrect because switching agents mid-titration is not indicated; the appropriate approach is to continue uptitrating the existing evidence-based agent.
Option D: Option D is incorrect because improved EF on GDMT does not mean HFrEF has resolved; beta-blockers must be continued indefinitely as withdrawal leads to recurrent LV dysfunction.
Option E: Option E is incorrect because digoxin is a negative chronotropic agent (vagotonic) — it slows, not accelerates, the heart rate; and it is not used to "create hemodynamic space" for beta-blocker uptitration.
2. A 52-year-old woman with known primary hypertension is brought to the emergency department by her husband after he found her confused and diaphoretic at home. She has a history of clonidine 0.3 mg twice daily for hypertension and reports she ran out of her medication three days ago and was unable to refill it due to a holiday weekend. Her BP is 208/118 mmHg, heart rate 112 bpm, and she is diaphoretic and tremulous. Fundoscopic exam shows grade II hypertensive retinopathy but no papilledema. Neurological exam shows confusion but no focal deficits. Urinalysis is normal.
Which of the following most accurately describes the diagnosis, the pathophysiology, and the immediate management priority?
A) This is clonidine withdrawal hypertensive urgency — abrupt cessation of central alpha-2 agonism has unmasked the upregulated peripheral sympathetic system, producing a catecholamine-excess state; the immediate priority is to restart clonidine 0.3 mg orally (the patient's usual dose) and provide IV labetalol for acute BP control given the mental status change; the clonidine patch is not appropriate for acute management given its 48-hour onset; admission for monitoring is warranted given the neurological symptoms; target BP reduction of approximately 25% over 24–48 hours to avoid cerebral hypoperfusion in chronically hypertensive vessels
B) This is a hypertensive emergency from untreated essential hypertension; oral nifedipine should be given immediately to achieve rapid blood pressure normalization within 1 hour
C) This is clonidine toxicity from rebound drug accumulation; clonidine should be permanently discontinued and sodium nitroprusside initiated
D) This is a pheochromocytoma crisis that was previously masked by clonidine suppression; the diagnostic priority is urinary metanephrines before any treatment is initiated
E) This is hypertensive encephalopathy from uncontrolled essential hypertension; the history of clonidine use is irrelevant to the current presentation; IV hydralazine is the agent of choice
ANSWER: A
Rationale:
This presentation is classic for clonidine withdrawal hypertensive urgency with features approaching a hypertensive emergency (BP 208/118 mmHg with mental status change). The three-day history of clonidine discontinuation after running out of medication, combined with the clinical triad of severe hypertension, tachycardia, and diaphoresis, establishes the diagnosis. The pathophysiology is adrenoceptor upregulation: during chronic clonidine therapy, central alpha-2-mediated suppression of sympathetic outflow leads to compensatory upregulation of peripheral adrenoceptors; abrupt drug withdrawal removes the central suppression, and the sensitized sympathetic system fires excessively — producing a catecholamine-excess state. Management has two simultaneous components: (1) addressing the underlying cause by restarting clonidine (0.3 mg orally at the usual dose) to re-establish central sympatholysis; (2) providing acute BP control with IV labetalol while waiting for oral clonidine to reload. The transdermal clonidine patch cannot be used for acute control because its 48-hour onset is too slow for the clinical urgency. The mental status change raises concern for hypertensive encephalopathy, mandating admission. BP reduction should target approximately 25% over 24–48 hours — rapid normalization risks cerebral ischemia in vessels adapted to chronic hypertension. The absence of papilledema and focal deficits is reassuring but does not exclude early encephalopathy.
Option B: Option B is incorrect because sublingual/oral nifedipine for rapid BP normalization is inappropriate — it causes unpredictable BP drops risking cerebral ischemia; and the diagnosis is not simple essential hypertension.
Option C: Option C is incorrect because clonidine withdrawal does not cause drug accumulation; it causes drug absence with receptor upregulation.
Option D: Option D is incorrect because the history of clonidine discontinuation completely explains the presentation; a pheochromocytoma workup may eventually be appropriate but is not the diagnostic priority in this acute setting.
Option E: Option E is incorrect because the clonidine history is central to the diagnosis and management.
3. A 46-year-old man with hypertension is referred after his blood pressure proved difficult to control despite three agents. His current regimen is losartan 100 mg, amlodipine 10 mg, and chlorthalidone 25 mg daily. BP is 168/96 mmHg. Secondary causes have been excluded. His physician adds bisoprolol 5 mg daily as a fourth agent. At 8 weeks, his BP is 148/90 mmHg — improved but still above target. A colleague suggests switching from bisoprolol to doxazosin or adding doxazosin to the current regimen. The treating physician consults the PATHWAY-2 evidence before deciding.
Based on PATHWAY-2, which of the following most accurately guides the next step?
A) Add doxazosin 4 mg daily — PATHWAY-2 showed doxazosin was the most effective fourth-line agent in patients with elevated plasma renin activity; this patient's response to bisoprolol indicates high renin physiology where doxazosin will be more effective
B) Replace bisoprolol with doxazosin — PATHWAY-2 showed bisoprolol was inferior to doxazosin in resistant hypertension; switching rather than adding avoids polypharmacy
C) Add spironolactone 25 mg daily as the fifth agent — PATHWAY-2 demonstrated spironolactone was superior to both bisoprolol and doxazosin as add-on therapy; however, the patient is already on four agents and spironolactone should be tried before bisoprolol is considered further; measure PRA and potassium before initiating
D) Continue bisoprolol and add doxazosin — PATHWAY-2 showed that combining a beta-blocker and alpha-blocker provides the most effective dual adrenergic blockade in resistant hypertension
E) Check plasma renin activity first — PATHWAY-2 demonstrated that the superiority of spironolactone over bisoprolol and doxazosin was most pronounced in patients with low PRA; if this patient's PRA is low, replacing or supplementing bisoprolol with spironolactone 25 mg daily would be pharmacologically optimal; if PRA is elevated, bisoprolol's renin-suppressing mechanism is more appropriate; potassium should also be checked before adding spironolactone given the existing chlorthalidone and losartan
ANSWER: E
Rationale:
PATHWAY-2 provided important insights not only about which agent is best (spironolactone) but also about the physiological predictors of response. The trial demonstrated that spironolactone's superior blood pressure reduction was most pronounced in patients with low plasma renin activity — indicating volume-dependent, aldosterone-mediated physiology where MR blockade directly addresses the underlying mechanism. Patients with higher PRA had relatively less differential benefit from spironolactone over bisoprolol. Before adding or switching to spironolactone, measuring PRA is therefore both pharmacologically rational and clinically informative. If PRA is low (indicating likely volume-dependent aldosterone excess), spironolactone is clearly the preferred addition — the PATHWAY-2 evidence is most strongly in its favor. Potassium must be checked before adding spironolactone, since this patient is on chlorthalidone (which lowers potassium) and losartan (which raises potassium) — the net potassium status determines safety. If PRA is not low, the evidence advantage of spironolactone over bisoprolol is less definitive, though spironolactone still provided greater overall BP reduction across the full trial population. Option C is partially correct in the spironolactone recommendation but incorrectly implies bisoprolol should not have been tried; the PATHWAY-2 evidence supports spironolactone as the preferred fourth-line agent, but the step-wise approach is appropriate.
Option A: Option A is incorrect because PATHWAY-2 showed bisoprolol (not doxazosin) was relatively more effective in higher-renin patients; and even then, spironolactone remained the most effective overall agent.
Option B: Option B is incorrect because PATHWAY-2 showed bisoprolol was superior to doxazosin (not inferior) — doxazosin was the least effective of the three active treatments.
Option D: Option D is incorrect because PATHWAY-2 did not demonstrate benefit from combining beta-blocker and alpha-blocker; doxazosin was the least effective fourth-line agent in the trial.
4. A 34-year-old woman with hypertension is 28 weeks pregnant. Her BP has been progressively rising and is now 158/102 mmHg. She has no proteinuria and no symptoms of severe preeclampsia. She was previously controlled on lisinopril 10 mg daily before pregnancy, which was appropriately discontinued when she became pregnant. Her obstetrician initiates labetalol 100 mg twice daily. At 32 weeks her BP is 148/96 mmHg — partially controlled but still above target (goal less than 140/90 mmHg in pregnancy). The obstetrician considers adding nifedipine extended-release 30 mg daily as a second agent.
Which of the following most accurately describes the pharmacological rationale for the labetalol-nifedipine combination and any relevant drug interaction concern?
A) The combination should be avoided — labetalol's beta-blockade and nifedipine's calcium channel blockade both reduce cardiac output through different mechanisms, creating additive hemodynamic compromise that risks fetal hypoperfusion
B) The combination of labetalol and nifedipine ER is pharmacologically rational and guideline-supported in pregnancy hypertension — labetalol reduces BP through combined alpha-1 and beta-1 blockade (reducing both peripheral resistance and cardiac output); nifedipine ER provides additional peripheral arteriolar vasodilation through L-type calcium channel blockade; these mechanisms are complementary and non-redundant; the historically reported concern about labetalol-nifedipine interaction causing excessive hypotension or neuromuscular blockade (extrapolated from intravenous nifedipine data and magnesium sulfate interaction studies) does not apply to oral extended-release nifedipine at therapeutic antihypertensive doses; the combination is used widely in clinical practice for gestational hypertension with reassuring safety data
C) Nifedipine must be avoided in pregnancy because all calcium channel blockers inhibit uterine contractions and would delay delivery if preterm labor occurs before 37 weeks gestation
D) The combination is appropriate but requires simultaneous initiation of a potassium supplement because labetalol and nifedipine both cause significant hypokalemia through complementary renal and cellular mechanisms
E) Nifedipine ER should replace labetalol rather than being added — combination antihypertensive therapy in pregnancy carries a fetal growth restriction risk that monotherapy does not
ANSWER: B
Rationale:
The combination of labetalol and nifedipine ER is widely used and guideline-supported for gestational hypertension requiring more than one antihypertensive agent. Labetalol provides BP reduction through combined alpha-1 blockade (reducing peripheral vascular resistance) and beta-1 blockade (reducing heart rate and cardiac output). Nifedipine ER provides complementary peripheral arteriolar vasodilation through L-type calcium channel blockade in vascular smooth muscle — a mechanistically distinct pathway from labetalol's adrenoceptor effects. This combination addresses BP through two non-redundant mechanisms with additive antihypertensive benefit. There was a historical concern about a potential interaction between nifedipine and labetalol, partly extrapolated from data on IV nifedipine (a formulation no longer used) and from studies of nifedipine with magnesium sulfate (used in preeclampsia). The oral extended-release nifedipine formulation used in antihypertensive therapy does not produce the rapid plasma level spikes of IV administration and does not have a clinically established harmful interaction with oral labetalol at antihypertensive doses. The combination is used globally for pregnancy hypertension.
Option A: Option A is incorrect because nifedipine ER (a DHP CCB) does not significantly reduce cardiac output at therapeutic doses — it reduces peripheral resistance; the "additive cardiac depression" concern applies to non-DHP CCBs combined with beta-blockers, not DHP CCBs.
Option C: Option C is incorrect because while nifedipine does have tocolytic properties (inhibiting uterine smooth muscle contractions), this is a pharmacological property used therapeutically and does not constitute a contraindication in a patient at 32 weeks where preterm delivery prevention is beneficial.
Option D: Option D is incorrect because neither labetalol nor nifedipine ER causes significant hypokalemia; potassium supplementation is not required for this combination.
Option E: Option E is incorrect because combination antihypertensive therapy in pregnancy is used when BP is inadequately controlled on one agent; it does not carry established fetal growth restriction risk beyond that associated with the hypertension itself.
5. A 61-year-old man with hypertension, benign prostatic hyperplasia, and no history of heart failure is on lisinopril 20 mg and amlodipine 5 mg daily. His BP is 144/88 mmHg — partially controlled. He has moderate lower urinary tract symptoms from BPH (IPSS score 18) despite tamsulosin 0.4 mg daily. His urologist and cardiologist discuss whether switching tamsulosin to doxazosin might address both the BPH symptoms and the residual hypertension with a single agent change.
Which of the following most accurately evaluates this pharmacological strategy?
A) The strategy is sound — tamsulosin and doxazosin are pharmacologically identical alpha-1 blockers; the only difference is that doxazosin is taken once daily in the evening while tamsulosin requires twice-daily dosing
B) The strategy has merit but an important limitation — doxazosin's non-selective alpha-1 blockade will provide both antihypertensive and BPH symptom benefit; however, doxazosin should replace tamsulosin rather than be added to it, as combining two alpha-1 blockers provides no additional BPH benefit and compounds orthostatic hypotension risk; the expected additional BP reduction from doxazosin (approximately 4–8 mmHg systolic at 4 mg) may bring his BP to target when added to his existing regimen; the key monitoring parameter is orthostatic hypotension, particularly during the first-dose period
C) The strategy is inappropriate — alpha-1 blockers are absolutely contraindicated in patients already on ACE inhibitors because the combination causes irreversible renal alpha-1 receptor desensitization that worsens CKD
D) The strategy has merit — doxazosin's non-selective alpha-1 blockade (affecting both vascular and prostatic smooth muscle) can simultaneously reduce peripheral vascular resistance for antihypertensive effect and relax prostatic/bladder neck smooth muscle for BPH symptom relief; it should replace tamsulosin (which is alpha-1A selective and provides minimal antihypertensive benefit) rather than being added; the orthostatic hypotension risk is higher with doxazosin than tamsulosin and requires patient counseling and careful dose titration; the ALLHAT cardiovascular caution regarding doxazosin should be considered — in this patient already on an ACEi and CCB, adding doxazosin as a third antihypertensive should be weighed against simply increasing amlodipine to 10 mg first
E) Doxazosin should replace both lisinopril and amlodipine in this patient — alpha-1 blockers provide superior antihypertensive efficacy compared to ACE inhibitors and CCBs in patients with BPH and do not require combination therapy
ANSWER: D
Rationale:
The pharmacological rationale for switching from tamsulosin to doxazosin in a hypertensive patient with BPH is sound in principle but requires careful consideration. Tamsulosin is alpha-1A receptor-selective — the alpha-1A subtype predominates in prostatic smooth muscle — which provides effective BPH symptom relief with minimal cardiovascular (antihypertensive) effect. This subtype selectivity is precisely why tamsulosin was developed: to treat BPH without causing significant orthostatic hypotension. Doxazosin is non-selective for alpha-1 subtypes, blocking alpha-1A (prostate, bladder neck) and alpha-1B (vascular smooth muscle) equally — providing both BPH symptom relief and meaningful antihypertensive activity. Switching from tamsulosin to doxazosin (rather than adding it) avoids duplicate alpha-1 blockade. However, the ALLHAT finding of higher cardiovascular event rates (particularly heart failure) with doxazosin compared to chlorthalidone is relevant — in a patient with existing hypertension partially controlled on an ACEi and CCB, the prescriber should consider whether simply uptitrating amlodipine to 10 mg would achieve BP target before adding a drug class with the ALLHAT caveat. If doxazosin is used, the orthostatic hypotension risk is meaningfully higher than tamsulosin given doxazosin's vascular alpha-1 blockade — first-dose counseling and bedtime dosing are essential. Option B is partially correct but insufficiently addresses the ALLHAT consideration and the BP uptitration alternative.
Option A: Option A is incorrect because tamsulosin and doxazosin are pharmacologically distinct in their receptor subtype selectivity — this distinction is clinically important.
Option C: Option C is incorrect because ACE inhibitors and alpha-1 blockers do not interact through renal receptor desensitization; this mechanism does not exist.
Option E: Option E is incorrect because alpha-1 blockers should not replace established antihypertensive agents with proven cardiovascular outcome data (ACEi, CCB); ALLHAT demonstrated inferior cardiovascular protection with doxazosin compared to thiazide-type diuretics.
6. A 41-year-old woman with newly diagnosed hypertension (BP 172/104 mmHg) is also found to have a 3.2 cm right adrenal mass on CT abdomen performed for an unrelated indication. Twenty-four-hour urine metanephrine is 4.2 mg/24 hours (normal less than 1.0 mg/24 hours) and normetanephrine is 9.8 mg/24 hours (normal less than 1.7 mg/24 hours). Pheochromocytoma is confirmed biochemically. The endocrinologist plans surgical resection in 6 weeks after adequate pharmacological preparation.
Which of the following most accurately describes the pharmacological preparation protocol and the sequence of drug initiation?
A) Start propranolol 40 mg twice daily immediately — non-selective beta-blockade provides the most complete adrenergic blockade for pheochromocytoma preparation and reduces the risk of intraoperative catecholamine surge
B) Start doxazosin 2 mg daily and increase to 8 mg daily over 2 weeks, then add metoprolol if tachycardia develops — this alpha-first approach uses a selective alpha-1 blocker to minimize the reflex tachycardia that accompanies alpha blockade
C) Start phenoxybenzamine 10 mg twice daily and titrate up (typically to 20–40 mg twice daily) over 1–2 weeks to achieve adequate alpha blockade, volume expansion, and blood pressure control; add a beta-blocker (propranolol or atenolol) only after at least 3–5 days of established alpha blockade if persistent tachycardia (heart rate above 100 bpm) requires treatment; never initiate beta-blockade before alpha-blockade is established — doing so risks catastrophic hypertensive crisis from unopposed alpha-1 vasoconstriction
D) Start labetalol 200 mg twice daily — its combined alpha and beta blockade simultaneously addresses both the hypertension and tachycardia of pheochromocytoma, and a single agent simplifies the preoperative preparation
E) Start metyrosine (alpha-methyl-p-tyrosine) as monotherapy — it inhibits tyrosine hydroxylase, the rate-limiting step in catecholamine synthesis, depleting the tumor's catecholamine stores and providing complete preoperative preparation without the need for receptor blockers
ANSWER: C
Rationale:
Preoperative pharmacological preparation for pheochromocytoma follows a specific, evidence-based sequence. The inviolable rule is alpha-blockade first, beta-blockade second — never the reverse. The rationale: the tumor secretes catecholamines that act on both alpha-1 receptors (vasoconstriction) and beta-2 receptors (vasodilation); these opposing effects are partially balanced. If a beta-blocker is given first, the beta-2-mediated vasodilation is removed while high circulating catecholamines continue to drive alpha-1 vasoconstriction — producing unopposed alpha-1-mediated catastrophic hypertensive crisis. Phenoxybenzamine is the preferred alpha-blocker for preoperative preparation because it is a non-competitive, irreversible alpha-blocker — it covalently alkylates alpha receptors and cannot be displaced by the massive catecholamine surges that occur during surgical tumor manipulation (which competitive blockers such as doxazosin or prazosin could be overwhelmed by). Standard preparation: phenoxybenzamine 10 mg twice daily, titrated over 1–2 weeks to achieve blood pressure control and orthostatic hypotension (indicating adequate alpha blockade); the resulting peripheral vasodilation allows volume expansion (correcting the chronic volume contraction caused by catecholamine-mediated vasoconstriction, which prevents severe hypotension after the tumor is removed intraoperatively). A beta-blocker is added only after several days of alpha blockade is established and only if tachycardia (HR above approximately 100 bpm) requires treatment. Dietary sodium liberalization and hydration are also part of preparation.
Option A: Option A is incorrect because starting a beta-blocker first risks the catastrophic hypertensive crisis from unopposed alpha-1 vasoconstriction.
Option B: Option B is incorrect because doxazosin is a competitive reversible alpha-blocker that can be displaced by intraoperative catecholamine surges; phenoxybenzamine's irreversibility is specifically advantageous.
Option D: Option D is incorrect because labetalol, while containing alpha-1 blocking activity, has a ratio of beta:alpha blockade of approximately 7:1 — the beta-blocking component predominates significantly; using labetalol as the sole agent does not provide adequate alpha blockade and risks the same unopposed alpha-1 vasoconstriction concern.
Option E: Option E is incorrect because metyrosine can be used as an adjunct to reduce catecholamine stores (particularly in metastatic pheochromocytoma) but is not used as sole monotherapy for standard preoperative preparation; receptor blockade with phenoxybenzamine is still required.
7. A 68-year-old man with hypertension, type 2 diabetes, and stage 3b CKD (eGFR 34 mL/min/1.73m2) presents with BP 162/92 mmHg. His current regimen is losartan 100 mg and amlodipine 10 mg daily. Potassium is 4.9 mEq/L and sodium is 137 mEq/L. His nephrologist is considering methyldopa as a third antihypertensive because the patient has seen it listed in pregnancy guidelines and assumes it is broadly safe. Which of the following most accurately evaluates the appropriateness of methyldopa in this patient?
A) Methyldopa is a reasonable but suboptimal third agent in this patient — it provides effective BP reduction through central alpha-2 agonism and does not significantly affect potassium (addressing the borderline elevated potassium concern); however, it has substantial adverse effects that limit its use outside pregnancy: sedation, dry mouth, depression, and a positive Coombs test in up to 20% of patients with rare hemolytic anemia; it also requires dose adjustment in renal impairment (active metabolites can accumulate); in a patient with CKD stage 3b and significant comorbidities, a better-tolerated alternative with a cleaner safety profile — such as a low-dose loop diuretic (appropriate at this eGFR) or a small dose of bisoprolol — is typically preferred over methyldopa outside pregnancy
B) Methyldopa is absolutely contraindicated in CKD because it is exclusively renally eliminated and causes severe toxic accumulation at eGFR below 40 mL/min/1.73m2
C) Methyldopa is the preferred third agent in diabetic CKD because its central sympatholytic mechanism specifically reduces the sympathetic overactivation that drives progression of diabetic nephropathy
D) Methyldopa should be added at its standard dose of 500 mg twice daily without dose adjustment — the active metabolite accumulation in CKD is clinically insignificant and does not cause additional adverse effects
E) Methyldopa is appropriate in this patient because its mechanism of action is identical to clonidine — both agents are alpha-2 agonists with identical adverse effect profiles — and clonidine is the gold standard third-line agent in resistant hypertension
ANSWER: A
Rationale:
Methyldopa is effective and safe in pregnancy — where it has over four decades of follow-up data — but its use outside pregnancy is limited by a significant adverse effect burden. It is converted to alpha-methylnorepinephrine in the CNS, which stimulates central alpha-2 receptors to reduce sympathetic outflow. While this mechanism effectively lowers blood pressure, the adverse effects include prominent sedation (due to central noradrenergic suppression affecting the locus coeruleus), dry mouth, depression, sexual dysfunction, and a positive direct Coombs test in up to 20% of patients on chronic therapy (rarely progressing to hemolytic anemia requiring drug discontinuation). In CKD, methyldopa and its metabolites require dose adjustment — the drug is partially renally eliminated and active metabolites can accumulate at lower eGFR, potentially intensifying adverse effects. For a 68-year-old man with diabetes and CKD stage 3b, who has no pregnancy indication for methyldopa and has multiple comorbidities that make sedation, depression, and cognitive effects particularly undesirable, a better-tolerated alternative is appropriate. A loop diuretic (torsemide — appropriate at eGFR 34 and providing BP reduction without potassium-raising risk) or a cardioselective beta-blocker at low dose would be better-tolerated options.
Option B: Option B is incorrect because methyldopa is not absolutely contraindicated in CKD; it requires dose reduction, not complete avoidance.
Option C: Option C is incorrect because methyldopa does not have a specific renoprotective mechanism in diabetic nephropathy; this is not an established pharmacological property.
Option D: Option D is incorrect because dose adjustment is required in renal impairment; standard dosing without adjustment risks adverse effect accumulation.
Option E: Option E is incorrect because while both methyldopa and clonidine are centrally acting sympatholytics, their mechanisms differ (methyldopa is a false neurotransmitter prodrug; clonidine directly stimulates alpha-2 receptors) and clonidine is not the gold standard third-line agent in resistant hypertension — that role is held by spironolactone per PATHWAY-2.
8. A 55-year-old man with hypertension, no heart failure, and no coronary artery disease presents with a 3-day history of severe tearing chest pain radiating to the back. CT angiography confirms type A aortic dissection involving the ascending aorta. His BP is 188/106 mmHg and heart rate is 102 bpm. He is alert and hemodynamically stable. The cardiac surgical team is preparing for emergent surgery. Which of the following correctly identifies the immediate pharmacological priority and the agent of choice?
A) Initiate IV sodium nitroprusside as the first agent — it provides the most rapid blood pressure reduction of any available agent and is the gold standard for aortic dissection
B) Initiate IV hydralazine — its selective arteriolar dilation reduces the systolic blood pressure driving the dissection without affecting heart rate, avoiding the risk of tachycardia that complicates other IV antihypertensives in the perioperative setting
C) Initiate IV nicardipine — the DHP CCB provides titratable arteriolar vasodilation and is preferred over labetalol in aortic dissection because it does not cause bradycardia, allowing the heart rate to compensate for vasodilation and maintain cardiac output
D) No pharmacological treatment is needed before surgery — the cardiac surgical team will manage hemodynamics intraoperatively; antihypertensive agents before surgery risk hypotension that compromises coronary and cerebral perfusion
E) Initiate IV labetalol — the combined alpha-1 and beta-1 blockade simultaneously reduces blood pressure (reducing the driving force propagating the dissection) and heart rate (reducing dP/dt — the rate of pressure rise — which determines shear stress on the aortic wall); this dual action is uniquely suited to aortic dissection; if BP is not controlled with labetalol alone, IV nitroprusside can be added but only after adequate beta-blockade is established to prevent reflex tachycardia from nitroprusside's vasodilation
ANSWER: E
Rationale:
Aortic dissection has two critical hemodynamic targets that must be addressed simultaneously: blood pressure (reducing the systolic driving pressure that propagates the dissection into the false lumen) and dP/dt — the rate of ventricular pressure rise, which determines the shear stress applied to the dissecting aortic wall with each heartbeat. Reducing dP/dt requires heart rate reduction and contractility reduction — both achieved through beta-1 blockade. Labetalol IV is uniquely pharmacologically suited to aortic dissection because its combined alpha-1 and beta-1 blockade addresses both targets simultaneously: alpha-1 blockade reduces peripheral resistance and BP; beta-1 blockade reduces heart rate, contractility, and dP/dt. Critically, labetalol does not cause reflex tachycardia — a critical advantage over pure vasodilators. If nitroprusside is used as an adjunct for refractory hypertension, it must only be added after adequate beta-blockade is established; nitroprusside's potent vasodilation without heart rate control would cause reflex tachycardia that dramatically increases dP/dt — potentially worsening the dissection. Target parameters in aortic dissection are typically systolic BP of 100–120 mmHg and heart rate below 60 bpm.
Option A: Option A is incorrect because nitroprusside without concomitant beta-blockade causes reflex tachycardia that worsens aortic shear stress; it is not the first-line agent.
Option B: Option B is incorrect because hydralazine causes significant reflex tachycardia through its pure arteriolar dilation — this dramatically increases dP/dt and is specifically harmful in aortic dissection.
Option C: Option C is incorrect because nicardipine (a DHP CCB) does not reduce heart rate and would cause reflex tachycardia through baroreceptor activation from its vasodilation; non-DHP CCBs are not used in aortic dissection with tachycardia because they require concomitant beta-blockade.
Option D: Option D is incorrect because immediate pharmacological BP and heart rate control is mandatory — every minute of uncontrolled hypertension with high dP/dt risks dissection propagation, rupture, or malperfusion of coronary arteries, the brain, or abdominal organs.
9. A 47-year-old man with hypertension and no other significant medical history is started on doxazosin 1 mg at bedtime, with plans to titrate to 4 mg for blood pressure control. Two weeks later he is seen in urgent care reporting that he has been unable to achieve or maintain an erection since starting the medication. He is distressed and asks whether the drug is causing this and what can be done.
Which of the following most accurately explains the pharmacological basis of his concern and the most appropriate response?
A) Doxazosin is causing erectile dysfunction through its blockade of alpha-1 receptors in penile vasculature, preventing the alpha-1-mediated vasoconstriction needed for penile tumescence; this is a predictable and irreversible adverse effect that requires permanent drug discontinuation
B) Doxazosin is unlikely to be causing erectile dysfunction — alpha-1 receptor blockade in penile smooth muscle actually facilitates erection by promoting relaxation of the corpus cavernosum; if anything, alpha-1 blockers tend to improve, not impair, erectile function; the temporal association may be coincidental; a more likely cause of new erectile dysfunction in a 47-year-old man starting antihypertensive therapy is the underlying hypertension itself or performance anxiety related to the medication; assessment should include sexual history, psychological factors, and consideration of other causes; if erectile dysfunction persists, phosphodiesterase-5 inhibitors can be used but require caution regarding additive hypotension with doxazosin
C) Doxazosin is definitively causing erectile dysfunction through central alpha-2 receptor stimulation — alpha-1 blockers cross the blood-brain barrier and stimulate hypothalamic alpha-2 receptors that suppress sexual arousal; the medication must be discontinued
D) Doxazosin causes retrograde ejaculation through alpha-1 blockade of the bladder neck and seminal vesicle smooth muscle, which the patient is misidentifying as erectile dysfunction; this adverse effect is permanent and requires drug discontinuation
E) Doxazosin-induced erectile dysfunction is dose-dependent and will resolve when the dose is reduced to 0.5 mg daily; no further investigation is needed
ANSWER: B
Rationale:
Alpha-1 adrenoceptors in penile smooth muscle (corpus cavernosum) normally mediate vasoconstriction and maintain flaccidity. During sexual arousal, parasympathetic activation releases nitric oxide, which via cGMP causes smooth muscle relaxation, arteriolar dilation, and cavernous engorgement — producing erection. Alpha-1 receptor blockade pharmacologically facilitates this process by reducing the sympathetically-mediated vasoconstriction that resists erection — if anything, alpha-1 blockers have been associated with improved erectile function in some studies, particularly in patients with benign prostatic hyperplasia. This is mechanistically opposite to drugs that impair erection (such as beta-blockers, which reduce sympathetically-mediated arousal response, or thiazide diuretics through vascular mechanisms). If the patient is reporting erectile dysfunction, the more likely causes are: the underlying hypertension itself (a well-established cause of endothelial dysfunction and erectile impairment); performance anxiety or nocebo effect from starting a new medication; or other comorbidities. Retrograde ejaculation (a distinct phenomenon caused by alpha-1 blockade of bladder neck smooth muscle preventing closure during ejaculation) can occur with alpha-1 blockers and might be confused with erectile dysfunction. If erectile dysfunction persists, PDE-5 inhibitors can be used — but the additive hypotension risk with doxazosin requires caution (start at the lowest PDE-5 inhibitor dose, ensure several hours between the two drugs). Option D is partially correct (retrograde ejaculation is a real alpha-1 blocker adverse effect) but incorrect in stating the patient is misidentifying it — the question asks about erectile dysfunction specifically, and retrograde ejaculation is a different symptom; it is not irreversible and does not require drug discontinuation.
Option A: Option A is incorrect because alpha-1 blockade in the penis does not impair erection; it facilitates it.
Option C: Option C is incorrect because doxazosin does not cause erectile dysfunction through central alpha-2 stimulation; this mechanism does not exist.
Option E: Option E is incorrect because the proposed dose-dependent mechanism is pharmacologically inverted — alpha-1 blockers do not cause erectile dysfunction in a dose-dependent manner.
10. A 73-year-old woman with severe treatment-resistant hypertension (BP 196/106 mmHg on five agents) is referred to a hypertension specialist. Her current regimen is lisinopril 40 mg, amlodipine 10 mg, chlorthalidone 25 mg, spironolactone 50 mg, and bisoprolol 10 mg daily. Adherence has been confirmed by urine drug screening. Her eGFR is 48 mL/min/1.73m2. Potassium is 4.6 mEq/L. Secondary causes have been thoroughly excluded. The specialist considers initiating minoxidil. Which of the following most accurately addresses the pharmacological preparation required before minoxidil is appropriate in this patient?
A) Minoxidil can be started immediately — the patient is already on five antihypertensives including a diuretic and a beta-blocker, which will prevent the fluid retention and reflex tachycardia that minoxidil causes; no additional preparation is needed
B) Minoxidil requires switching bisoprolol to carvedilol first — carvedilol's combined alpha and beta blockade provides superior protection against minoxidil-induced reflex tachycardia compared to bisoprolol's beta-1 selective blockade alone
C) Minoxidil is absolutely contraindicated in this patient because her eGFR of 48 mL/min/1.73m2 prevents adequate renal elimination of minoxidil; all loop diuretics are also contraindicated at this eGFR, making minoxidil preparation impossible
D) Before starting minoxidil, chlorthalidone should be switched to a loop diuretic (torsemide or furosemide) at an adequate dose — minoxidil causes profound sodium and fluid retention severe enough that thiazide-type diuretics are generally insufficient; the bisoprolol is already appropriately in place to prevent reflex tachycardia; at eGFR 48, a loop diuretic is also more appropriate than chlorthalidone for diuresis; minoxidil should be started at 2.5 mg daily and titrated slowly with close monitoring of BP, weight, and electrolytes
E) Minoxidil requires adding IV furosemide as a pre-treatment for seven days before oral minoxidil initiation to deplete extracellular fluid volume and create diuretic reserve for the sodium retention minoxidil will cause
ANSWER: D
Rationale:
Minoxidil is reserved for truly refractory hypertension — it is one of the most potent oral antihypertensives available but its adverse effect profile requires pharmacological preparation. Two mandatory co-prescriptions are required: a beta-blocker (to block reflex tachycardia from baroreceptor-mediated sympathetic activation) and a loop diuretic (to manage minoxidil's profound sodium and fluid retention). This patient has bisoprolol 10 mg daily already in place — the beta-blocker requirement is met. However, she is on chlorthalidone 25 mg — a thiazide-type diuretic. At eGFR 48 mL/min/1.73m2, chlorthalidone's efficacy is substantially reduced (thiazides require adequate tubular secretion for NCC delivery, which is impaired at this eGFR). More importantly, minoxidil's sodium retention is frequently too severe for thiazide-type diuretics to manage adequately even at normal GFR — a loop diuretic is required. Torsemide (preferred over furosemide for its predictable ~80% oral bioavailability) should replace chlorthalidone before minoxidil is initiated. Minoxidil is started at the lowest available dose (2.5 mg daily) and titrated with close monitoring of blood pressure, body weight (to detect fluid retention), and electrolytes. The potassium of 4.6 mEq/L on spironolactone requires monitoring as the loop diuretic may lower it.
Option A: Option A is incorrect because chlorthalidone is insufficient diuretic coverage for minoxidil-associated fluid retention; switching to a loop diuretic is required before initiation.
Option B: Option B is incorrect because bisoprolol adequately prevents reflex tachycardia through beta-1 blockade; switching to carvedilol is not required.
Option C: Option C is incorrect because minoxidil undergoes hepatic sulfation (not renal elimination) — it does not require dose adjustment in CKD; and loop diuretics are more appropriate, not contraindicated, at eGFR 48.
Option E: Option E is incorrect because IV furosemide pre-treatment for seven days is not a standard preparation protocol; oral loop diuretic transition is what is required.
11. A 58-year-old man with hypertension, HFrEF (EF 35%), type 2 diabetes, and stage 3a CKD (eGFR 54 mL/min/1.73m2) presents for comprehensive medication review. His current regimen is: carvedilol 25 mg twice daily, sacubitril/valsartan 97/103 mg twice daily, eplerenone 50 mg daily, empagliflozin 10 mg daily, and furosemide 40 mg daily. BP is 146/84 mmHg. His cardiologist wants to add a fifth antihypertensive agent. She proposes adding bisoprolol 5 mg daily for additional rate control (heart rate currently 72 bpm) and BP reduction.
Which of the following most accurately evaluates the appropriateness of this proposal?
A) Adding bisoprolol is appropriate — bisoprolol's higher beta-1 selectivity will provide better rate control than carvedilol and the combination of two beta-blockers will improve outcomes in HFrEF through additive receptor blockade
B) Adding bisoprolol is appropriate as long as the carvedilol dose is simultaneously reduced — the two beta-blockers together at half-doses provide equal efficacy with fewer adverse effects than either at full dose
C) Adding bisoprolol to carvedilol constitutes dual beta-blockade — two agents blocking overlapping beta-1, beta-2, and (for carvedilol) alpha-1 receptors simultaneously; this redundancy provides no additional cardiovascular benefit and compounds risks of bradycardia, AV block, and hemodynamic depression in a patient with HFrEF; the heart rate of 72 bpm on carvedilol is well within the acceptable range for HFrEF; if additional BP control is needed, amlodipine 5 mg daily is the mechanistically correct addition — L-type vascular calcium channel blockade is absent from the current regimen, amlodipine is hemodynamically neutral in HFrEF (V-HeFT III), does not affect potassium, and does not interact adversely with any current agent
D) Adding bisoprolol is appropriate because eplerenone's MR blockade reduces aldosterone-driven potassium retention, creating hemodynamic space for additional beta-blockade without the usual hyperkalemia risk from dual RAAS therapy
E) Adding bisoprolol is contraindicated because beta-blockers cannot be combined with empagliflozin — the SGLT2 inhibitor's osmotic diuresis creates volume depletion that is dangerously compounded by beta-blocker-mediated reduction in cardiac output
ANSWER: C
Rationale:
Adding bisoprolol to carvedilol in this patient constitutes dual beta-blockade — two agents with overlapping receptor pharmacology (both block beta-1; carvedilol additionally blocks beta-2 and alpha-1; bisoprolol is beta-1 selective but still overlaps on the critical beta-1 receptor). This combination provides no additional pharmacological benefit: the beta-1 receptors relevant to HFrEF are already occupied by carvedilol at 25 mg twice daily. Combining two beta-blockers compounds risks of excessive bradycardia, AV conduction delay, and further negative inotropy in a patient with already-compromised ventricular function (EF 35%). The heart rate of 72 bpm is entirely appropriate for HFrEF — guidelines typically target resting heart rate of 60–70 bpm in HFrEF, and there is no indication for further rate reduction in an asymptomatic patient with a well-controlled heart rate. For additional BP control, amlodipine is the correct pharmacological choice: its mechanism (vascular L-type calcium channel blockade) is not represented in the current five-drug regimen; it is hemodynamically neutral in HFrEF (V-HeFT III demonstrated no worsening of EF, hospitalization, or mortality); it does not affect potassium (important given eplerenone and sacubitril/valsartan); it does not interact adversely with any current agent; and it requires no renal dose adjustment at any eGFR.
Option A: Option A is incorrect because dual beta-blockade does not improve HFrEF outcomes through additive receptor blockade — the guideline approach is one evidence-based beta-blocker optimized to target dose.
Option B: Option B is incorrect because splitting the dose across two beta-blockers provides no pharmacological benefit and introduces unnecessary complexity.
Option D: Option D is incorrect because the rationale for adding bisoprolol is pharmacologically disconnected from eplerenone's mechanism; aldosterone blockade does not create "hemodynamic space" for additional beta-blockade.
Option E: Option E is incorrect because beta-blockers are not contraindicated with empagliflozin; the combination is used safely in clinical practice with standard volume monitoring.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.